* BioMarin Pharmaceutical Inc BMRN.OQ reported quarterly
adjusted earnings of 55 cents per share for the quarter ended
January 1, higher than the same quarter last year, when the
company reported EPS of 21 cents. The mean expectation of
twenty eight analysts for the quarter was for earnings of 52
cents per share. Wall Street expected results to range from 29
cents to 69 cents per share.
* Revenue rose 28.3% to $745.74 million from a year ago;
analysts
expected $700.18 million.
* BioMarin Pharmaceutical Inc's reported EPS for the quarter
was
55 cents.
* The company reported quarterly net income of $106.08
million.
* BioMarin Pharmaceutical Inc shares had fallen by 0.2% this
quarter and lost 27.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 5.3%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 21 "strong buy" or "buy," 8
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for BioMarin
Pharmaceutical Inc is 93.00
This summary was machine generated from LSEG data October 30 at
02:49 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 0.52 0.55 Beat
Jun. 30 2024 0.35 0.56 Beat
Mar. 31 2024 0.35 0.46 Beat
Dec. 31 2023 0.23 0.18 Missed